负载后禁食间隔与患糖尿病风险之间的剂量反应关系:来自中国多个中心的队列研究
Xiaohan Xu1,2, Duolao Wang1, Uazman Alam3,4,5,6
1Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK.
BMJ open diabetes research & care
|December 4, 2025
概括
负载后禁食间隔,衡量葡萄糖调节,预测中国成年人糖尿病风险和缓解潜力. 将其与禁食葡萄糖相结合,可以改善早期风险识别和预防策略.
科学领域:
- 内分泌学 在内分泌学.
- 代谢健康 代谢健康
- 人口健康 人口健康
背景情况:
- 仅仅是禁食葡萄糖不足以检测早期的葡萄糖调节障碍.
- 后负荷 - 禁食间隔 (2小时后负荷血葡萄糖减去禁食血葡萄糖) 可能表明动态失调.
- 它在中国人口的血糖恶化和缓解中的作用需要澄清.
研究的目的:
- 为了研究后负载-禁食间隔和中国大型队列中的四个血糖结局之间的剂量反应关系.
- 评估发生糖尿病,发生糖尿病前期,从糖尿病前期到糖尿病的进展,以及恢复到正常的葡萄糖耐受性.
- 为了评估血糖变化后负载 - 禁食间隔的预测值.
主要方法:
- 对3094名没有糖尿病的成年人进行分析,随访时间为3.24年.
- 用于检测结果的口服葡萄糖耐受性测试 (OGTT) (世卫组织1999年和ADA标准).
- 有限制立方线的离散时间危险模型用于分析关联,对共变量进行调整.
主要成果:
- 较高的负载后禁食间隔与不良的代谢概况以及糖尿病和糖尿病前期的风险增加相关.
- 较低的差距与恢复正常葡萄糖耐受性有关.
- 负载后 - 禁食间隔证明了与血糖结果的非线性关系,与禁食血葡萄糖相结合时,预测得到了改善.
结论:
- 负载后 - 禁食间隔是一个独立的,非线性标志物,用于确定血糖风险和缓解潜力.
- 将负载后 - 禁食间隔与禁食血葡萄糖相结合,可以提高风险分层和临床效用.
- 这一OGTT衍生的指标支持早期识别糖尿病风险和有针对性的预防.
相关概念视频
Diabetes Mellitus: Type 2 and Gestational
4.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.3K
Diabetes: Symptoms, Diagnosis, and Complications
2.0K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.0K
Insulin: Dosing Regimen and Adverse Effects
658
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
658
Hypoglycemia and Glucagon
778
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
778
Pathophysiology of Diabetes
3.1K
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
3.1K
Dipeptidyl Peptidase 4 Inhibitors
559
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
559


